All In Biotech

Drug Trial Radar · NCT04650451

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

220

Planned (sponsor's estimate)

Start

Dec 7, 2020

Primary completion

Dec 31, 2025

Study completion Jan 2, 2027

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.

Conditions

  • HER-2 Gene Amplification
  • HER2-positive Gastric Cancer
  • HER2-positive Breast Cancer
  • HER-2 Protein Overexpression
  • Solid Tumor, Adult

Interventions

  • chimeric antigen receptor (CAR) T cell therapyBiological

    HER2-targeted dual-switch CAR-T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of BPX-603Time frame: 35 days from time of BPX-603 infusion
  2. Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)Time frame: through Phase 1 completion, up to 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • University of California San Diego (UCSD)

    La Jolla, California

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • John Theurer Cancer Center, Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.